



**Ref. No.: EIKO/BSE/2024-25/40**

**Date: 19<sup>th</sup> October, 2024**

To,  
Corporate Services Department,  
**BSE Limited,**  
Phiroze Jeejeebhoy Towers,  
1st Floor, Dalal Street,  
Fort, Mumbai - 400001.

**Scrip Code: EIKO 540204**

**Subject: Outcome of the Board Meeting**

Dear Sir/Madam,

Pursuant to the Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), and amendments thereto, this is to inform that the Meeting of the Board of Directors of the Company held today i.e., on Saturday, 19<sup>th</sup> October, 2024, Board, inter-alia, considered and approved the Unaudited Financial Results (Standalone & Consolidation basis) for the Quarter and half year ended 30<sup>th</sup> September, 2024.

The Statutory Auditors have carried out a “Limited Review” of the Unaudited Financial Results for the Quarter and half year ended 30<sup>th</sup> September, 2024. Further, Pursuant to the Regulation 33 of the Listing Regulations, we are enclosing herewith a copy of the Unaudited Financial Results and Limited Review Report of the Statutory Auditors of the Company.

The said results shall be published in one English and one vernacular newspaper as required. This intimation is also available on the Company’s website at [www.eikolifesciences.com](http://www.eikolifesciences.com).

The Meeting was commenced at 6.30 PM and concluded at 8.15 PM.

Please take the same on your records.

**For Eiko Lifesciences Limited**

---

**Chintan Doshi**  
**Company Secretary and Compliance Officer**  
**Membership No: A 36190**

**Limited Review Report on Standalone Unaudited Quarterly and Six Months ended financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

**To the Board of Directors**  
**Eiko Lifesciences Limited**

1. We have reviewed the accompanying statement of Unaudited Standalone Financial Results of Eiko LifeSciences Limited (the "Company") for the quarter and half year ended September 30, 2024 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial result prepared in accordance with applicable Principles laid down in Indian Accounting Standards 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under section 133 of companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement

**For Thanawala & Company**  
Chartered Accountants  
Firm Reg. No.: 110948W



**CA Vijay Thanawala**  
Proprietor  
Membership No.: 015632



**Place: Mumbai**  
**Date: 19<sup>th</sup> October 2024**

**UDIN: 24015632BKGWZ13037**



**EIKO LIFESCIENCES LIMITED**  
(CIN: L65993MH1977PLC258134)

**Statement of standalone unaudited financial results for the quarter and six months ended 30<sup>th</sup> September 2024**

(₹ in lakhs)

Sr. No.	Particulars	Quarter ended			Half year ended		Year ended
		30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	31-03-2024
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue from operations	773.92	1,075.04	641.27	1,848.95	1,292.05	2,792.93
	Other income	13.07	26.23	2.81	39.29	5.54	17.61
	<b>Total revenue</b>	<b>786.98</b>	<b>1,101.26</b>	<b>644.09</b>	<b>1,888.25</b>	<b>1,297.59</b>	<b>2,810.54</b>
2	<b>Expenses</b>						
	Cost of Material consumed	661.36	992.16	660.21	1,653.53	1,263.76	2,720.48
	Changes in inventories of finished stock and work-in-progress	34.10	(0.16)	(89.26)	33.94	(89.71)	(179.07)
	Employee benefits expense	5.91	5.32	4.95	11.22	10.29	22.07
	Depreciation and amortization expense	16.31	16.53	16.06	32.83	32.11	66.25
	Finance Cost	3.58	2.88	6.10	6.46	9.47	14.21
	Other expenses	37.71	38.41	29.86	76.12	44.64	68.17
	<b>Total expenses</b>	<b>758.96</b>	<b>1,055.14</b>	<b>627.93</b>	<b>1,814.09</b>	<b>1,270.56</b>	<b>2,712.12</b>
3	<b>Profit/(Loss) from ordinary activities before tax</b>	<b>28.03</b>	<b>46.13</b>	<b>16.16</b>	<b>74.15</b>	<b>27.03</b>	<b>98.42</b>
4	<b>Tax expense:</b>						
	(1) Current tax	4.58	8.57	-	13.14	-	9.82
	(2) Earlier year's Tax	-	-	-	-	-	0.03
	(4) Deferred tax	2.64	2.88	4.07	5.52	6.93	13.42
5	<b>Profit/(Loss) from ordinary activities after tax</b>	<b>20.81</b>	<b>34.68</b>	<b>12.09</b>	<b>55.49</b>	<b>20.10</b>	<b>75.15</b>
6	<b>Other Comprehensive Income (OCI)</b>						
	<u>Item that will not be reclassified to profit or loss</u>						
	Gain/(Loss) on recognised on fair valuation of Financial Assets	-	-	-	-	-	3.21
	Income tax relating to these items	-	-	-	-	-	(0.81)
	<b>Total Other Comprehensive Income</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>2.40</b>
	<b>Profit/(Loss) for the Period</b>	<b>20.81</b>	<b>34.68</b>	<b>12.09</b>	<b>55.49</b>	<b>20.10</b>	<b>77.55</b>
	Paid up Equity Share Capital (Face Value of Rs. 10 each)	1,287.28	1,287.28	997.95	1,287.28	997.95	1,287.28
7	<b>Earnings Per Share (EPS) (Not annualised)</b>						
	(1) Basic	0.16	0.27	0.12	0.43	0.24	0.73
	(2) Diluted	0.16	0.27	0.12	0.43	0.24	0.73



**EIKO LIFESCIENCES LIMITED**  
(CIN: L65993MH1977PLC258134)

**Standalone unaudited statement of assets and liabilities for the period ended 30<sup>th</sup> September 2024**

(₹ in lakhs)

Particulars	30-09-2024 (Unaudited)	31-03-2024 (Audited)	30-09-2023 (Unaudited)
<b>ASSETS</b>			
<b>Non-current assets</b>			
Property, Plant and Equipment	1,307.94	1,356.51	1,360.70
<u>Financial Assets</u>			
Investments	706.07	401.77	406.85
Loans and Advances	484.58	422.70	177.66
	<b>2,498.59</b>	<b>2,180.99</b>	<b>1,945.21</b>
<b>Current assets</b>			
Inventories	270.33	338.56	133.24
<u>Financial Assets</u>			
Investments	342.42	-	-
Trade Receivables	1,406.62	1,313.38	1,009.99
Cash and cash equivalents	312.61	1,334.60	495.04
Other Current Assets	647.45	106.34	406.23
	<b>2,979.43</b>	<b>3,092.88</b>	<b>2,044.49</b>
<b>TOTAL ASSET</b>	<b>5,478.02</b>	<b>5,273.87</b>	<b>3,989.70</b>
<b>EQUITY AND LIABILITIES</b>			
<b>EQUITY</b>			
Equity Share capital	1,287.28	1,287.28	997.95
Other Equity	3,836.03	3,780.54	2,712.84
	<b>5,123.31</b>	<b>5,067.83</b>	<b>3,710.79</b>
<b>LIABILITIES</b>			
<b>Non-current liabilities</b>			
Deferred Tax Liabilities	61.12	55.60	49.11
	<b>61.12</b>	<b>55.60</b>	<b>49.11</b>
<b>Current liabilities</b>			
<u>Financial Liabilities</u>			
Current Borrowings	42.62	-	86.02
Trade payables	221.66	138.05	135.32
Other financial liabilities	-	-	1.37
Current Tax Liabilities	9.92	6.44	-
Provisions	1.55	1.50	1.50
Other current Liability	17.84	4.46	5.59
	<b>293.59</b>	<b>150.44</b>	<b>229.80</b>
<b>TOTAL LIABILITIES</b>	<b>5,478.02</b>	<b>5,273.87</b>	<b>3,989.70</b>



**EIKO LIFESCIENCES LIMITED**  
(CIN: L65993MH1977PLC258134)

**Standalone unaudited statement of cash flows for the six months ended 30<sup>th</sup> September 2024**

(₹ in lakhs)

Particulars	30-09-2024 (Unaudited)	31-03-2024 (Audited)	30-09-2023 (Unaudited)
<b>A. CASH FLOW FROM OPERATING ACTIVITIES</b>			
Net (loss) / profit before tax	74.15	98.42	27.03
<b>Adjustments for</b>			
Depreciation and Amortisation Expense	30.08	66.25	32.11
Profit from sale of Fixed assets	(0.01)	-	-
Dividend Income	-	(0.03)	(0.03)
Finance Costs	6.46	14.21	9.47
Interest Income classified as investing cash flow	(37.88)	(18.15)	(5.51)
<b>Operating profit before working capital changes</b>	<b>72.80</b>	<b>160.70</b>	<b>63.07</b>
<b>Working capital adjustments:</b>			
Increase / (Decrease) in Trade and Other Payables	83.61	33.52	30.79
Increase / (Decrease) in Provisions	0.05	(3.05)	(3.04)
Increase / (Decrease) in Other current Liabilities	16.87	(0.98)	0.16
Increase / (Decrease) in Other Financial Liabilities	-	(5.36)	(3.99)
(Increase) / Decrease in Inventories	68.24	(247.81)	(42.48)
(Increase) / Decrease in Trade Receivables	(93.25)	(602.82)	(299.43)
(Increase) / Decrease in Other Current Assets	(541.11)	(38.78)	(338.67)
<b>Cash generated from / (used in) operations</b>	<b>(392.79)</b>	<b>(704.56)</b>	(593.59)
Direct taxes paid (Net of Refunds)	(13.14)	(3.41)	-
<b>Net cash (used in) / from generated from operating activities</b>	<b>(405.94)</b>	<b>(707.97)</b>	<b>(593.59)</b>
<b>B. CASH FLOW FROM INVESTING ACTIVITIES</b>			
Sale/(Purchase) of Investments	(646.72)	(396.42)	(401.50)
Sale/(Purchase) of Fixed Assets	18.50	(34.65)	(4.70)
Profit from sale of Fixed Assets	0.01	-	-
Income from dividend	-	0.03	0.03
Proceeds from Deposits, Loans and Advances	(61.88)	358.00	490.78
Interest Income	37.88	18.15	5.51
<b>Net cash (used in) / generated from investing activities</b>	<b>(652.21)</b>	<b>(54.90)</b>	<b>90.12</b>
<b>C. CASH FLOW FROM FINANCING ACTIVITIES</b>			
Proceeds from issue of shares	-	2,050.45	748.46
Interest paid	(6.46)	(14.21)	(9.47)
Proceeds /(Repayment) from borrowings	42.62	-	86.02
<b>Net cash (used in) / from financing activities</b>	<b>36.16</b>	<b>2,036.24</b>	<b>825.01</b>
<b>Net decrease in cash and cash equivalents (A+B+C)</b>	<b>(1,021.99)</b>	<b>1,273.36</b>	<b>321.54</b>
Cash and cash equivalents at the beginning of the year	1,334.60	61.24	173.50
<b>Cash and cash equivalents at the end of the year</b>	<b>312.61</b>	<b>1,334.60</b>	<b>495.04</b>

**Limited Review Report on Consolidated Unaudited Quarterly and Six Months ended financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

**To the Board of Directors  
Eiko LifeSciences Limited**

1. We have reviewed the accompanying statement of Unaudited Consolidated Financial Results of Eiko LifeSciences Limited (the "Parent") and its Associate (the parent and its associate referred to as Group) for the quarter and half year ended September 30, 2024 (the "Statement") attached herewith, being submitted by the parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parents's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. The statement includes the results of following entity:

Parent	
1	Eiko LifeSciences Limited
Subsidiary	
2	Eiko Scientific Solutions LLP
Associate	
3	Reflux Pharmaceuticals Private Limited

4. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial result prepared in accordance with applicable Principles laid down in Indian Accounting Standards 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under section 133 of companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement







6. We did not review the interim financial results of associate included in the Statement whose interim financial information reflects total revenues of INR 990.58 lakhs and net profit after tax of INR 24.26 lakhs for the half year ended 30<sup>th</sup> September 2024 as considered in the Statement. These interim financial results have been reviewed by other auditors and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of associate is based solely on the reports of the other auditors and the procedures performed by us as stated above.

Our conclusion on the Statement is not modified in respect of the above matter.

**For Thanawala & Company**

Chartered Accountants

**Firm Reg. No.: 110948W**



**CA Vijay Thanawala**

Proprietor

**Membership No.: 015632**

**Place: Mumbai**

**Date: 19<sup>th</sup> October 2024**

**UDIN: 24015632BKGWZJ4063**



**EIKO LIFESCIENCES LIMITED**  
(CIN: L65993MH1977PLC258134)

**Statement of consolidated unaudited financial results for the quarter and six months ended 30<sup>th</sup> September 2024**

(₹ in lakhs)

Sr. No.	Particulars	Quarter ended		Half year ended
		30.09.2024	30.06.2024	30.09.2024
		(Unaudited)	(Unaudited)	(Unaudited)
<b>1</b>	Revenue from operations	815.51	1,075.04	1,890.55
	Other income	13.07	26.23	39.29
	<b>Total revenue</b>	<b>828.58</b>	<b>1,101.26</b>	<b>1,929.84</b>
<b>2</b>	<b>Expenses</b>			
	Cost of Material consumed	685.76	992.16	1,677.93
	Changes in inventories of finished stock and work-in-progress	34.10	(0.16)	33.94
	Employee benefits expense	6.71	5.32	12.02
	Depreciation and amortization expense	16.31	16.53	32.83
	Finance Cost	3.58	2.88	6.46
	Other expenses	46.88	38.41	85.28
	<b>Total expenses</b>	<b>793.32</b>	<b>1,055.14</b>	<b>1,848.46</b>
<b>3</b>	<b>Profit/(Loss) from ordinary activities before tax</b>	<b>35.26</b>	<b>46.13</b>	<b>81.38</b>
<b>4</b>	<b>Tax expense:</b>			
	(1) Current tax	6.83	8.57	15.40
	(2) Earlier year's Tax	-	-	-
	(4) Deferred tax	2.64	2.88	5.52
<b>5</b>	<b>Profit/(Loss) from ordinary activities after tax</b>	<b>25.78</b>	<b>34.68</b>	<b>60.46</b>
	Share of Profit from Associates (net of tax)	2.37	2.45	4.82
<b>6</b>	<b>Net profit after taxes and share of profit of Associates</b>	<b>28.15</b>	<b>37.13</b>	<b>65.29</b>
<b>7</b>	<b>Other Comprehensive Income (OCI)</b>	-	-	-
	<i>Item that will not be reclassified to profit or loss</i>			
	Gain/(Loss) on recognised on fair valuation of Financial Assets	-	-	-
	Income tax relating to these items	-	-	-
	<b>Total Other Comprehensive Income (OCI)</b>	-	-	-
	<b>Profit/(Loss) for the Period</b>	<b>28.15</b>	<b>37.13</b>	<b>65.29</b>
	Paid up Equity Share Capital (Face Value of Rs. 10 each)	1,287.28	1,287.28	1,287.28
<b>8</b>	<b>Earnings Per Share (EPS) (Not annualised)</b>			
	(1) Basic	0.22	0.29	0.51
	(2) Diluted	0.22	0.29	0.51





**EIKO LIFESCIENCES LIMITED**  
(CIN: L65993MH1977PLC258134)

**Consolidated unaudited statement of assets and liabilities for the period ended 30<sup>th</sup> September 2024**

(₹ in lakhs)	
Particulars	30-09-2024 (Unaudited)
<b>ASSETS</b>	
<b>Non-current assets</b>	
Property, Plant and Equipment	1,307.94
<b>Financial Assets</b>	
Investments	705.89
Loans and Advances	484.58
	<b>2,498.42</b>
<b>Current assets</b>	
Inventories	270.33
<b>Financial Assets</b>	
Trade Receivables	1,425.20
Cash and cash equivalents	313.18
Other Current Assets	985.44
	<b>2,994.14</b>
<b>TOTAL ASSET</b>	<b>5,492.56</b>
<b>EQUITY AND LIABILITIES</b>	
<b>EQUITY</b>	
Equity Share capital	1,287.28
Other Equity	3,845.83
	<b>5,133.11</b>
<b>LIABILITIES</b>	
<b>Non-current liabilities</b>	
Deferred Tax Liabilities	61.12
	<b>61.12</b>
<b>Current liabilities</b>	
<b>Financial Liabilities</b>	
Current Borrowings	42.62
Trade payables	222.76
Current Tax Liabilities	11.65
Provisions	1.55
Other current Liability	19.75
	<b>298.33</b>
<b>TOTAL LIABILITIES</b>	<b>5,492.56</b>



**EIKO LIFESCIENCES LIMITED**  
(CIN: L65993MH1977PLC258134)

Consolidated unaudited statement of cash flows for the six months ended 30<sup>th</sup> September 2024

(₹ in lakhs)

Particulars	30-09-2024 (Unaudited)
<b>A. CASH FLOW FROM OPERATING ACTIVITIES</b>	
Net (loss) / profit before tax	81.38
<b>Adjustments for</b>	
Depreciation and Amortisation Expense	30.08
Share of Profit from Associates (net of tax)	4.82
Profit on sale of Fixed Assets	(0.01)
Finance Costs	6.46
Interest Income classified as investing cash flow	(37.88)
<b>Operating profit before working capital changes</b>	<b>84.85</b>
<b>Working capital adjustments:</b>	
Increase / (Decrease) in Trade and Other Payables	84.71
Increase / (Decrease) in Provisions	0.05
Increase / (Decrease) in Other current Liabilities	20.51
(Increase) / Decrease in Inventories	68.24
(Increase) / Decrease in Trade Receivables	(111.82)
(Increase) / Decrease in Other Current Assets	(879.10)
<b>Cash generated from / (used in) operations</b>	<b>(732.57)</b>
Direct taxes paid (Net of Refunds)	(15.40)
<b>Net cash (used in) / from generated from operating activities</b>	<b>(747.96)</b>
<b>B. CASH FLOW FROM INVESTING ACTIVITIES</b>	
Sale/(Purchase) of Investments	(304.12)
Sale/(Purchase) of Fixed Assets	18.50
Profit on sale of Fixed Assets	0.01
Proceeds from Deposits, Loans and Advances	(61.88)
Interest Income	37.88
<b>Net cash (used in) / generated from investing activities</b>	<b>(309.61)</b>
<b>C. CASH FLOW FROM FINANCING ACTIVITIES</b>	
Interest paid	(6.46)
Proceeds /(Repayment) from borrowings	42.62
<b>Net cash (used in) / from financing activities</b>	<b>36.16</b>
<b>Net decrease in cash and cash equivalents (A+B+C)</b>	<b>(1,021.42)</b>
Cash and cash equivalents at the beginning of the year	1,334.60
<b>Cash and cash equivalents at the end of the year</b>	<b>313.18</b>



## NOTES

1. The above unaudited Standalone and Consolidated financial results for the quarter and half year ended 30<sup>th</sup> September 2024 were reviewed by the audit committee of the board on 19<sup>th</sup> October 2024 and thereafter approved by the board of directors of the company at their meeting held on 19<sup>th</sup> October 2024.
2. The above unaudited Standalone and Consolidated financial results for the quarter and half year ended 30<sup>th</sup> September 2024 were reviewed by the statutory auditor of the company under regulation 33 of Securities & Exchange board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended. An unqualified limited review report was issued by them there on.
3. The group has a single business segment, namely "Speciality & Fine Chemicals" therefore in the context of Ind As 108, disclosure of segment information is not applicable.
4. During the period, the company successfully acquired a 25.01% equity stake in Reflux Pharmaceuticals Private Limited ("RPPL"), thereby making it an associate company of Eiko LifeSciences Limited. Additionally, the company has incorporated wholly owned LLP i.e., Eiko Scientific Solutions LLP. As a result, consolidated financial results have been prepared and presented for the Quarter and Half Year ending 30<sup>th</sup> September 2024. Since this is the first period in which consolidated financial statements are being reported, comparative figures for the previous financial year are not available.
5. The unaudited financial results for the quarter and six months ended September 30, 2024 ("the financial results") comprise the standalone results of Eiko LifeSciences Limited ("the Company") and the consolidated results of the Company including its Wholly owned LLP and Associate (collectively referred to as 'the Group'). These financial results have been prepared in accordance with Indian Accounting Standards ("Ind AS") notified under Section 133 of the Companies Act 2013 read with the Companies (Indian Accounting Standards) Rules, 2015 (as amended)
6. Figures for the previous period have been regrouped/ reclassified wherever necessary to conform to current period's classification.
7. The figures for the corresponding previous quarter/ year have been regrouped/reclassified wherever necessary, to make them comparable.

**For Eiko LifeSciences Limited**

**Laxmikant Kabra**  
Chairman  
DIN: 00061346



**Date: 19<sup>th</sup> October 2024**

**Place: Thane**